NCT05589792View on ClinicalTrials.gov

Acetazolamide on REM OSA

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2025

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

Placebo oral capsule

Placebo before sleep for 3 nights before the study (inclusive)

DRUG

Acetazolamide

Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER